Interactions on record — worth a quick check against your medications. Based on 2 of 4 ingredients. Check your meds →
Dietary supplement

OmegaEnergy Oil Ingredients & Drug Interactions

by EnergyFirst

Liquid Category: Fat/fatty Acid
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

OmegaEnergy Oil is a dietary supplement by EnergyFirst with 4 active ingredients. Its ingredients are commonly taken for brain and cognitive health, eye and vision health, fetal and infant development.Based on those ingredients, 375 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Omega-3 Fatty Acids. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of OmegaEnergy Oil by EnergyFirst

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 6 of its 6 active ingredients.
  • No proprietary blends here — you can verify the dose of every single component.

OmegaEnergy Oil contains 6 active ingredients: omega-3 fatty acids (DHA), polyunsaturated fat, omega-6 fatty acids, omega-9 fatty acids, medium chain triglycerides, and monounsaturated fat. These are a blend of different fat types delivered in liquid form.

The product also contains inactive ingredients — organic flax seed, sunflower seed, sesame seed, and pumpkin seed oils — which serve as carriers or binders.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: brain, joint and heart health.
  • We looked for evidence on: Age-related cognitive decline, Alzheimer disease, Cognitive function, Cognitive impairment, Cardiovascular disease (CVD), Coronary heart disease (CHD) — and 4 related terms.
  • The strongest evidence on file: Docosahexaenoic Acid (dha) is rated "Possibly Effective" for Hyperlipidemia (Natural Medicines).
  • Also on file: Omega-6 Fatty Acids is rated "Possibly Ineffective" for Cardiovascular disease (CVD), Hyperlipidemia.
  • Also on file: Docosahexaenoic Acid (dha) is rated "Possibly Ineffective" for Age-related cognitive decline, Alzheimer disease, Cognitive function.

The omega-3 fatty acids (DHA) in this product are rated Possibly Effective for high cholesterol (hyperlipidemia) and preterm labor. However, DHA is rated Possibly Ineffective for cognitive function and attention deficit-hyperactivity disorder (ADHD).

Omega-6 fatty acids are rated Possibly Ineffective for high cholesterol, child development, cardiovascular disease, and multiple sclerosis. The evidence we hold doesn't establish the effectiveness of polyunsaturated fat, omega-9 fatty acids, medium chain triglycerides, or monounsaturated fat for any condition.

The evidence, ingredient by ingredient Docosahexaenoic Acid (dha) Omega-6 Fatty Acids

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 2 of the 2 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 2 of 2.
  • General safety write-ups exist for 2 of 2.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

DHA is generally well tolerated at typical supplement doses for most adults. The most common side effects are belching, fishy aftertaste, loose stools, and nausea — usually mild and self-limiting.

Rare serious side effects include increased bleeding risk at high doses. A small number of trial participants reported rash, warmth in the hands, acne, or increased hair loss, though it's unclear if these were directly caused by DHA.

DHA is rated Likely Safe in pregnancy and lactation, though it's often recommended only under a doctor's guidance and from a purified, low-mercury source. DHA does pass into breast milk and is generally considered acceptable — check with your doctor on dose and source.

Omega-6 fatty acids are rated Likely Safe in pregnancy but Possibly Unsafe in lactation; talk with your doctor before taking omega-6 supplements. The safety data we hold for polyunsaturated fat, omega-9 fatty acids, medium chain triglycerides, and monounsaturated fat in pregnancy or lactation is not on file.

Side effects, ingredient by ingredient Docosahexaenoic Acid (dha) Omega-6 Fatty Acids

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 1 of the 2 matched ingredients can interact with medications — Docosahexaenoic Acid (dha).
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; diabetes medications.
  • For scale: 375 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking OmegaEnergy Oil, check with your doctor or pharmacist if you take blood thinners (like warfarin or clopidogrel), blood pressure medications, or diabetes medications. DHA may increase bleeding risk with anticoagulants, lower blood pressure further with antihypertensives, and raise blood sugar despite antidiabetes drugs — each a Moderate concern that warrants a conversation with your own healthcare provider.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

This product may help with high cholesterol if DHA is your goal, but it carries Moderate interactions with blood thinners, blood pressure medications, and diabetes drugs — all of which need discussion with your doctor or pharmacist before you start. If you take any of those medication types, or if you're pregnant or breastfeeding, check with your own healthcare provider first.

The fishy aftertaste and loose stools are common but usually mild.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 2 of 6 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Apr 22, 2016.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about OmegaEnergy Oil, straight from the product label.

Brand EnergyFirst
Net contents 17 fl. Oz.; 500 mL
Market status On market
Date entered into DSLD Apr 22, 2016
DSLD ID 58469
Product type Fat/fatty Acid
Supplement form Liquid
Dietary claims / uses Nutrient, All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Organic
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for OmegaEnergy Oil by EnergyFirst, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Tbsp
Maximum serving Sizes:
2 Tbsp
Servings per container
33
IngredientAmount% DV
Calories130 {Calories}--
Calories from Fat130 {Calories}--
Omega-3 Fatty Acids6.5 Gram(s)--
Saturated Fat1 Gram(s)6%
Polyunsaturated Fat9 mg--
Omega-6 Fatty Acids2.4 Gram(s)--
Omega-9 Fatty Acids2.5 Gram(s)--
Total Fat14 Gram(s)22%
Medium Chain Triglycerides233 mg--
Monounsaturated Fat2.5 mg--

Other ingredients: organic Flax seed Oil, organic Sunflower seed Oil, organic Sesame seed Oil, organic Pumpkin seed Oil

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
General Statements

ESSENTIAL FATS Scientific blend of all essential fatty acids in their ideal ratios.

HEALTHY BODY Omega fatty acids promote brain, joint and heart health.*

IMMUNITY BOOST Contains naturally occurring traces of vitamins, minerals and antioxidants essential for immune system.*

100% NATURAL

Formulation

CERTIFIED ORGANIC Unique blend of cold-pressed, unrefined, certified organic seed oils.

No fillers, No artificial coloring or flavorings. No preservatives.

CERTIFIED ORGANIC OMEGA OILS

Certified organic by QAI

FDA Disclaimer Statement

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Formula

6500mg of Omega-3 per serving

100% Natural -Contains all essential fats in their ideal ratio

Brand IP Statement(s)

FEEL THE DIFFERENCE

OmegaEnergy Oil tastes great in EnergyFirst shakes, or when blended with balsamic vinegar and mustard as salad dressing or when added to many other recipes or foods. Visit www.energyfirst.com for more product information.

FDA Statement of Identity

DIETARY SUPPLEMENT

Storage

Keep Refrigerated

Can be frozen to prolong freshness.

Suggested/Recommended/Usage/Directions

Gently shake bottle before each use. Do not heat or use for frying.

Directions: Add 1-2 tablespoons to meal or shake. Recommended use twice per day.

Seals/Symbols

QUALITY ASSURANCE INTERNATIONAL CERTIFIED ORGANIC

See for yourself

OmegaEnergy Oil by EnergyFirst label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in OmegaEnergy Oil by EnergyFirst

These are the 4 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Tbsp Dosage formLiquid Servings per container33 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Omega-3 Fatty Acids

Interacts with
375 drugs
6.5 Gram(s) per serving

DHA is an omega-3 fatty acid found in fatty fish and algae that is a building block for the brain, nervous system, and eyes. It is widely used and gen...

Omega-3 Fatty Acids monograph & interactions

Omega-6 Fatty Acids

No known
interactions
2.4 Gram(s) per serving

Omega-6 fatty acids are essential fats your body needs but cannot make on its own, and most people get plenty from everyday foods like vegetable oils,...

Omega-6 Fatty Acids monograph & interactions

Omega-9 Fatty Acids

2.5 Gram(s) per serving

Medium Chain Triglycerides

233 mg per serving

Other (inactive) ingredients: Organic Flax seed Oil, Organic Sunflower seed Oil, Organic Sesame seed Oil, Organic Pumpkin seed Oil. These complete the product’s ingredient list but are not active constituents.

Interaction report

OmegaEnergy Oil by EnergyFirst Drug Interactions

Want to check YOUR meds against OmegaEnergy Oil?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
375Drugs
375 Moderate

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in OmegaEnergy Oil with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.

Omega-3 Fatty Acids3 drug types · 375 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, DHA may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs.
Although some clinical evidence suggests that DHA might reduce collagen-stimulated platelet aggregation and thromboxane release, most clinical evidence suggests that DHA alone does not affect blood clotting. However, theoretically, when given in combination with EPA as fish oil, concomitant use with anticoagulant or antiplatelet drugs (including aspirin) might increase risk of bleeding.

Likelihood Unlikely Evidence B
Antidiabetes Drugs

Theoretically, taking DHA with antidiabetes drugs might reduce the effects of these medications.
In people with type 2 diabetes, including those taking oral hypoglycemic medications, DHA seems to increase fasting blood glucose levels.

Likelihood Possible Evidence B
Antihypertensive Drugs

Theoretically, taking DHA with antihypertensive drugs might increase the risk of hypotension.
Fish oils containing DHA can lower blood pressure and might have additive effects in patients treated with antihypertensives; use with caution.

Likelihood Probable Evidence B
The maker

Brand information

Manufacturer and brand details for OmegaEnergy Oil, from the product label.

EnergyFirst

See all EnergyFirst products
Phone Number
1-888-883-6374
Pharmacist Counseling Corner

OmegaEnergy Oil by EnergyFirst: Common Questions

Does OmegaEnergy Oil by EnergyFirst interact with any medications?
Yes. Based on its ingredients, OmegaEnergy Oil has a known interaction with 375 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
OmegaEnergy Oil contains 4 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take this while I'm pregnant?
DHA is rated Likely Safe in pregnancy and is often recommended during prenatal care, but only under your doctor's guidance. Make sure to choose a purified, low-mercury source. Talk with your doctor before starting.
Is this safe if I'm breastfeeding?
DHA passes into breast milk and is generally considered acceptable, but you'll want to check with your doctor on the right dose and source for you. Omega-6 fatty acids are rated Possibly Unsafe in lactation, so definitely discuss this with your doctor first.
What are the most common side effects?
Belching, fishy aftertaste, loose stools, and nausea are the most common — usually mild and temporary. Some people also report flatulence or heartburn.
Will this really help my cholesterol?
The DHA in this product is rated Possibly Effective for high cholesterol. Results vary by person, so talk with your doctor about whether this fits your cholesterol plan.
Does this help with ADHD or focus?
DHA is rated Possibly Ineffective for both ADHD and cognitive function in the data we hold. If focus is your goal, this product isn't established to help.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if OmegaEnergy Oil is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

OmegaEnergy Oil label
Sources

Sources & How We Checked

OmegaEnergy Oil's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 69 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Docosahexaenoic Acid (dha) 49 references
  1. Akedo I, Ishikawa H, Nakamura T, et al. Three cases with familial adenomatous polyposis diagnosed as having malignant lesions in the course of a long-term trial using docosahexanoic acid (DHA)-concentrated fish oil capsules (abstract). Jpn J Clin Oncol PubMed
  2. Prisco D, Paniccia R, Bandinelli B, et al. Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. Thromb Res 1998;1:105-12.
  3. Grimsgaard S, Bonaa KH, Hansen JB, Nordoy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr 1997;66:649-59.
  4. Toft I, Bonaa KH, Ingebretsen OC, et al. Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. A randomized, controlled trial. Ann Intern Med 1995;123:911-8.
  5. Sacks FM, Hebert P, Appel LJ, et al. Short report: the effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the trials of hypertension prevention. J Hypertens 1994;12:209-13.
  6. Vandongen R, Mori TA, Burke V, et al. Effects on blood pressure of omega 3 fats in subjects at increased risk of cardiovascular disease. Hypertension 1993;22:371-9. PubMed
  7. FDA. Center for Food Safety and Applied Nutrition. Letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart disease. Available at: http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-Rpt0272-38-Appendix-D-Reference
  8. Pedersen HS, Mulvad G, Seidelin KN, et al. N-3 fatty acids as a risk factor for haemorrhagic stroke. Lancet 1999;353:812-3. PubMed
  9. Ito Y, Suzuki K, Imai H, et al. Effects of polyunsaturated fatty acids on atrophic gastritis in a Japanese population. Cancer Lett 2001;163:171-8. PubMed
  10. Kris-Ehterton PM, Harris WS, Appel LJ, et al. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57. PubMed
  11. Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002;76:1007-15.. PubMed
  12. Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003;160:996-8.. PubMed
  13. Leng GC, Smith FB, Fowkes FG, et al. Relationship between plasma essential fatty acids and smoking, serum lipids, blood pressure and haemostatic and rheological factors. Prostaglandins Leukot Essent Fatty Acids 1994;51:101-8. PubMed
  14. Nelson GJ, Schmidt PS, Bartolini GL, et al. The effect of dietary docosahexaenoic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Lipids 1997;32:1129-36. PubMed
  15. Wheaton DH, Hoffman DR, Locke KG, et al. Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa. Arch Ophthalmol 2003;121:1269-78. PubMed
  16. Malcolm CA, McCulloch DL, Montgomery C, et al. Maternal docosahexaenoic acid supplementation during pregnancy and visual evoked potential development in term infants: a double blind, prospective, randomised trial. Arch Dis Child Fetal Neonatal Ed 2003;88: DOI
  17. Sanjurjo P, Ruiz-Sanz JI, Jimeno P, et al. Supplementation with docosahexaenoic acid in the last trimester of pregnancy: maternal-fetal biochemical findings. J Perinat Med 2004;32:132-6.
  18. Montgomery C, Speake BK, Cameron A, et al. Maternal docosahexaenoic acid supplementation and fetal accretion. Br J Nutr 2003;90:135-45. DOI
  19. Lauritzen L, Hoppe C, Straarup EM, Michaelsen KF. Maternal fish oil supplementation in lactation and growth during the first 2.5 years of life. Pediatr Res 2005;58:235-42. PubMed
  20. Hawkes JS, Bryan DL, Makrides M, et al. A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha. Am J Clin Nutr 2002;75:75
  21. Uauy R, Hoffman DR, Mena P, et al. Term infant studies of DHA and ARA supplementation on neurodevelopment: Results of randomized controlled trials. J Pediatr 2003;143:S17-25. PubMed
  22. Decsi, T., Campoy, C., and Koletzko, B. Effect of N-3 polyunsaturated fatty acid supplementation in pregnancy: the Nuheal trial. Adv.Exp Med Biol 2005;569:109-113. PubMed
  23. Mori, T. A., Bao, D. Q., Burke, V., Puddey, I. B., and Beilin, L. J. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 1999;34(2):253-260. PubMed
  24. Otto, S. J., van Houwelingen, A. C., and Hornstra, G. The effect of supplementation with docosahexaenoic and arachidonic acid derived from single cell oils on plasma and erythrocyte fatty acids of pregnant women in the second trimester. Prostaglandins Le PubMed
  25. Helland, I. B., Saugstad, O. D., Smith, L., Saarem, K., Solvoll, K., Ganes, T., and Drevon, C. A. Similar effects on infants of n-3 and n-6 fatty acids supplementation to pregnant and lactating women. Pediatrics 2001;108(5):E82. PubMed
  26. Nestel, P., Shige, H., Pomeroy, S., Cehun, M., Abbey, M., and Raederstorff, D. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am.J.Clin.Nutr. 2002;76(2):326-330. PubMed
  27. Woodman, R. J., Mori, T. A., Burke, V., Puddey, I. B., Barden, A., Watts, G. F., and Beilin, L. J. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients PubMed
  28. Jensen, C. L., Voigt, R. G., Prager, T. C., Zou, Y. L., Fraley, J. K., Rozelle, J. C., Turcich, M. R., Llorente, A. M., Anderson, R. E., and Heird, W. C. Effects of maternal docosahexaenoic acid intake on visual function and neurodevelopment in breastfed
  29. Theobald, H. E., Goodall, A. H., Sattar, N., Talbot, D. C., Chowienczyk, P. J., and Sanders, T. A. Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women. J Nutr 2007;137(4):973-978.
  30. Mischoulon D, Best-Popescu C, Laposata M, et al. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008;18(9):639-645. PubMed
  31. Birch EE, Carlson SE, Hoffman DR, et al. The DIAMOND (DHA Intake And Measurement Of Neural Development) Study: a double-masked, randomized controlled clinical trial of the maturation of infant visual acuity as a function of the dietary level of docosahexa
  32. Carlson SE, Colombo J, Gajewski BJ, Gustafson KM, Mundy D, Yeast J, Georgieff MK, Markley LA, Kerling EH, Shaddy DJ. DHA supplementation and pregnancy outcomes. Am J Clin Nutr. 2013 Apr;97(4):808-15. PubMed
  33. Escamilla-Nuñez MC, Barraza-Villarreal A, Hernández-Cadena L, Navarro-Olivos E, Sly PD, Romieu I. Omega-3 fatty acid supplementation during pregnancy and respiratory symptoms in children. Chest. 2014 Aug;146(2):373-82. PubMed
  34. Fu YQ, Zheng JS, Yang B, Li D. Effect of individual omega-3 fatty acids on the risk of prostate cancer: a systematic review and dose-response meta-analysis of prospective cohort studies. J Epidemiol. 2015;25(4):261-74. PubMed
  35. Imhoff-Kunsch B, Stein AD, Villalpando S, Martorell R, Ramakrishnan U. Docosahexaenoic acid supplementation from mid-pregnancy to parturition influenced breast milk fatty acid concentrations at 1 month postpartum in Mexican women. J Nutr. 2011 Feb;141(2): PubMed
  36. Judge MP, Cong X, Harel O, Courville AB, Lammi-Keefe CJ. Maternal consumption of a DHA-containing functional food benefits infant sleep patterning: an early neurodevelopmental measure. Early Hum Dev. 2012 Jul;88(7):531-7. PubMed
  37. Mulder KA, King DJ, Innis SM. Omega-3 fatty acid deficiency in infants before birth identified using a randomized trial of maternal DHA supplementation in pregnancy. PLoS One. 2014 Jan 10;9(1):e83764. PubMed
  38. Richardson AJ, Burton JR, Sewell RP, Spreckelsen TF, Montgomery P. Docosahexaenoic acid for reading, cognition and behavior in children aged 7-9 years: a randomized, controlled trial (the DOLAB Study). PLoS One. 2012;7(9):e43909. PubMed
  39. Drugs in Pregnancy and Lactation 2012;25(4);3-4
  40. FDA announces qualified health claims for omega-3 fatty acids. Available at: https://www.fda.gov/Food/LabelingNutrition/ucm072756.htm. Accessed April 15 2019.
  41. Breastfeeding and the use of human milk. Section on Breastfeeding. Pediatrics. 2012;129(3):e827-41. PubMed
  42. Zhang Z, Fulgoni VL, Kris-Etherton PM, Mitmesser SH. Dietary Intakes of EPA and DHA Omega-3 Fatty Acids among US Childbearing-Age and Pregnant Women: An Analysis of NHANES 2001-2014. Nutrients. 2018;10(4). PubMed
  43. Montgomery P, Spreckelsen TF, Burton A, Burton JR, Richardson AJ. Docosahexaenoic acid for reading, working memory and behavior in UK children aged 7-9: A randomized controlled trial for replication (the DOLAB II study). PLoS One. 2018;13(2):e0192909. PubMed
  44. Marc I, Piedboeuf B, Lacaze-Masmonteil T, et al. Effect of maternal docosahexaenoic acid supplementation on bronchopulmonary dysplasia-free survival in breastfed preterm infants: A randomized clinical trial. JAMA. 2020;324(2):157-167. PubMed
  45. Fougère H, Bilodeau JF, Lavoie PM, et al. Docosahexaenoic acid-rich algae oil supplementation on breast milk fatty acid profile of mothers who delivered prematurely: a randomized clinical trial. Sci Rep 2021;11(1):21492. PubMed
  46. Garmendia ML, Casanello P, Flores M, Kusanovic JP, Uauy R. The effects of a combined intervention (docosahexaenoic acid supplementation and home-based dietary counseling) on metabolic control in obese and overweight pregnant women: the MIGHT study. Am J O PubMed
  47. Christifano DN, Gustafson KM, Carlson SE, et al. Maternal docosahexaenoic acid exposure needed to achieve maternal-newborn EQ. Nutrients 2022;14(16):3300. PubMed
  48. Vizzari G, Morniroli D, Alessandretti F, et al. Comparative analysis of docosahexaenoic acid (DHA) content in mother's milk of term and preterm mothers. Nutrients 2022;14(21):4595. PubMed
  49. Yang Y, Li G, Li F, et al. Impact of DHA from algal oil on the breast milk DHA levels of lactating women: A randomized controlled trial in China. Nutrients 2022;14(16):3410. PubMed

See these in context on the Docosahexaenoic Acid (dha) monograph →

Omega-6 Fatty Acids 20 references
  1. Godley PA. Essential fatty acid consumption and risk of breast cancer. Breast Cancer Res Treat 1995;35:91-5. PubMed
  2. Newcomer LM, King IB, Wicklund KG, Stanford JL. The association of fatty acids with prostate cancer risk. Prostate 2001;47:262-8. DOI
  3. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate. Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: National Academy Press, 2005. Available at: http://www.nap.edu/books/03 DOI
  4. Colter, A. L., Cutler, C., and Meckling, K. A. Fatty acid status and behavioural symptoms of attention deficit hyperactivity disorder in adolescents: a case-control study. Nutr J 2008;7:8. PubMed
  5. Yamada, T., Strong, J. P., Ishii, T., Ueno, T., Koyama, M., Wagayama, H., Shimizu, A., Sakai, T., Malcom, G. T., and Guzman, M. A. Atherosclerosis and omega-3 fatty acids in the populations of a fishing village and a farming village in Japan. Atheroscler
  6. Conklin, S. M., Manuck, S. B., Yao, J. K., Flory, J. D., Hibbeln, J. R., and Muldoon, M. F. High omega-6 and low omega-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosom.Med. 2007;69(9):932-934.
  7. Richardson, A. J., Cyhlarova, E., and Ross, M. A. Omega-3 and omega-6 fatty acid concentrations in red blood cell membranes relate to schizotypal traits in healthy adults. Prostaglandins Leukot.Essent.Fatty Acids 2003;69(6):461-466. PubMed
  8. Assies, J., Lok, A., Bockting, C. L., Weverling, G. J., Lieverse, R., Visser, I., Abeling, N. G., Duran, M., and Schene, A. H. Fatty acids and homocysteine levels in patients with recurrent depression: an explorative pilot study. Prostaglandins Leukot.Es PubMed
  9. Chiplonkar, S. A., Agte, V. V., Tarwadi, K. V., Paknikar, K. M., and Diwate, U. P. Micronutrient deficiencies as predisposing factors for hypertension in lacto-vegetarian Indian adults. J Am Coll.Nutr 2004;23(3):239-247. PubMed
  10. Mamalakis, G., Kiriakakis, M., Tsibinos, G., Hatzis, C., Flouri, S., Mantzoros, C., and Kafatos, A. Depression and serum adiponectin and adipose omega-3 and omega-6 fatty acids in adolescents. Pharmacol.Biochem.Behav. 2006;85(2):474-479. PubMed
  11. Okuyama, H., Ichikawa, Y., Sun, Y., Hamazaki, T., and Lands, W. E. Cancers common in the USA are stimulated by omega 6 fatty acids and large amounts of animal fats, but suppressed by omega 3 fatty acids and cholesterol. World Rev Nutr Diet. 2007;96:143-1
  12. Martinez-Ramirez, M. J., Palma, S., Martinez-Gonzalez, M. A., Delgado-Martinez, A. D., de la Fuente, C., and Delgado-Rodriguez, M. Dietary fat intake and the risk of osteoporotic fractures in the elderly. Eur.J Clin Nutr 2007;61(9):1114-1120. PubMed
  13. Sonestedt, E., Gullberg, B., and Wirfalt, E. Both food habit change in the past and obesity status may influence the association between dietary factors and postmenopausal breast cancer. Public Health Nutr 2007;10(8):769-779. PubMed
  14. Simopoulos, A. P. The omega-6/omega-3 fatty acid ratio, genetic variation, and cardiovascular disease. Asia Pac.J Clin Nutr 2008;17 Suppl 1:131-134.
  15. Harris, W. S., Mozaffarian, D., Rimm, E., Kris-Etherton, P., Rudel, L. L., Appel, L. J., Engler, M. M., Engler, M. B., and Sacks, F. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition DOI
  16. Godley, P. A., Campbell, M. K., Gallagher, P., Martinson, F. E., Mohler, J. L., and Sandler, R. S. Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiol.Biomarkers Prev. 1996;5(11):889-895.
  17. Lee E, Kim H, Kim H, Ha EH, Chang N. Association of maternal omega-6 fatty acid intake with infant birth outcomes: Korean Mothers and Children's Environmental Health (MOCEH). Nutr J 2018;17(1):47. PubMed
  18. Pawelczyk T, Trafalska E, Pawelczyk A, Kotlicka-Antczak M. Differences in omega-3 and omega-6 polyunsaturated fatty acid consumption in people at ultra-high risk of psychosis, first-episode schizophrenia, and in healthy controls. Early Interv Psychiatry 2
  19. Gardner KG, Gebretsadik T, Hartman TJ, et al. Prenatal omega-3 and omega-6 polyunsaturated fatty acids and childhood atopic dermatitis. J Allergy Clin Immunol Pract. 2020;8(3):937-944. PubMed
  20. Luo J, Ge H, Sun J, Hao K, Yao W, Zhang D. Associations of dietary ?-3, ?-6 fatty acids consumption with sleep disorders and sleep duration among adults. Nutrients 2021;13(5):1475. PubMed

See these in context on the Omega-6 Fatty Acids monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring